Abstract:
:The management of advanced prostate cancer, specifically metastatic castrate-resistant prostate cancer (mCRPC), remains a therapeutic challenge. Sipuleucel-T (Provenge; APC8015) was approved by the FDA in 2010 for the treatment of asymptomatic or minimally symptomatic mCRPC patients, and it remains the only FDA-approved immunotherapy for prostate cancer of any indication to date. Given the continued need to improve therapeutics in patients with advanced prostate cancer, as well as recent enthusiasm for cancer immunotherapy, there is a wide range of ongoing trials evaluating combinations of sipuleucel-T with other therapeutics. Additional trials are aiming to expand the application of sipuleucel-T to prostate cancer patients beyond the mCRPC setting. Ongoing challenges include understanding the full mechanism of action of sipuleucel-T, optimizing the sequence of sipuleucel-T in relation to other therapies for mCRPC in clinical practice, and the identification of surrogate markers to predict survival benefit in clinical trials.
journal_name
Expert Rev Vaccinesjournal_title
Expert review of vaccinesauthors
Wei XX,Fong L,Small EJdoi
10.1586/14760584.2015.1099437subject
Has Abstractpub_date
2015-01-01 00:00:00pages
1529-41issue
12eissn
1476-0584issn
1744-8395journal_volume
14pub_type
杂志文章,评审abstract::This section deals with how new knowledge of the development of cellular immunity in the neonatal period informs vaccine development and reviews the immune responses of the most vulnerable group of newborns, those born prematurely, to vaccines. It describes how the development of future vaccine strategies relies on a ...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/14760584.3.4.339
更新日期:2004-08-01 00:00:00
abstract:INTRODUCTION:Biologic disease-modifying anti-rheumatic drugs (bDMARDS) are increasingly used in clinical practice for a variety of conditions. Due to concerns surrounding persistence of drug levels and resulting immunosuppression, current case reports recommend against live vaccine administration in the first year of l...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1080/14760584.2019.1599286
更新日期:2019-05-01 00:00:00
abstract::Current treatments for lung cancer are far from optimal. Several immunotherapeutic strategies involving vaccines incorporating different tumor-associated antigens to induce immune responses against tumors are being tested in clinical trials internationally. Although small, benefits have indeed been observed from the e...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/erv.10.12
更新日期:2010-03-01 00:00:00
abstract::Vaccine manufacturing processes are designed to meet present and upcoming challenges associated with a growing vaccine market and to include multi-use facilities offering a broad portfolio and faster reaction times in case of pandemics and emerging diseases. The final products, from whole viruses to recombinant viral ...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/14760584.2015.1067144
更新日期:2015-01-01 00:00:00
abstract::Conjugate vaccines using diphtheria toxoid variant (CRM(197)), diphtheria toxoid and tetanus toxoid (TT) as carrier protein may induce immune interactions (interference or impairment as measured by lower antibody levels, or enhancement [higher antibody levels]) when coadministered with other vaccines. Immune enhanceme...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/erv.11.142
更新日期:2011-11-01 00:00:00
abstract::Combination vaccines have been used for many years in the USA as part of the primary infant immunization series. However, the current program still requires up to 24 injections by 18 months of age. The Advisory Committee on Immunization Practices in the USA recommends the use of combination vaccines whenever possible....
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/erv.09.59
更新日期:2009-07-01 00:00:00
abstract::Active immunotherapy aimed at the stimulation of tumor-specific T cells has established itself within the clinic as a therapeutic option to treat cancer. One strategy is the use of so-called peptides that mimic genuine T-cell epitopes as vaccines to activate tumor-specific T cells. In various clinical trials, differen...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/14760584.2014.862499
更新日期:2014-01-01 00:00:00
abstract::The Keystone Symposia conference, Challenges of Global Vaccine Development, attracted approximately 440 scientists, physicians and students from all around the world. The conference goal was to share newly acquired knowledge regarding vaccine-induced immunity, novel technologies, childhood vaccines, preclinical models...
journal_title:Expert review of vaccines
pub_type:
doi:10.1586/14760584.7.1.21
更新日期:2008-02-01 00:00:00
abstract::Through the continuous efforts of several generations, China has become one of the few countries in the world that is capable of independently addressing all the requirements by the Expanded Program on Immunization. Regulatory science is applied to continuously improve the vaccine regulatory system. Passing the prequa...
journal_title:Expert review of vaccines
pub_type: 历史文章,杂志文章,评审
doi:10.1586/14760584.2015.1012503
更新日期:2015-05-01 00:00:00
abstract:INTRODUCTION:There is a growing interest in developing curative strategies for HIV infection. Therapeutic vaccines are one of the most promising approaches. We will review the current knowledge and the new challenges in this research field. Areas covered: PubMed and ClinicalTrial.gov databases were searched to review t...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1080/14760584.2017.1322513
更新日期:2017-06-01 00:00:00
abstract:INTRODUCTION:Although much progress has been made in the last decade(s) toward development of effective cancer vaccines, there are still important obstacles to therapeutic successes. New generations of cancer vaccines will benefit from a combination adjuvant approach that targets multiple branches of the immune respons...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1080/14760584.2018.1434000
更新日期:2018-03-01 00:00:00
abstract::Immunotherapy is a promising means to fight cancer, prompting a steady increase in clinical trials and correlative laboratory studies in this field. As antitumor T cells play central roles in immunity against malignant diseases, most immunotherapeutic protocols aim to induce and/or strengthen their function. Various t...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/14760584.2013.843456
更新日期:2013-11-01 00:00:00
abstract::Nontypeable Haemophilus influenzae (NTHi) is a predominant organism of the upper respiratory nasopharyngeal microbiota. Its disease spectrum includes otitis media, sinusitis, non-bacteremic pneumonia and invasive infections. Protein-based vaccines to prevent NTHi infections are needed to alleviate these infections in ...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/14760584.2016.1156539
更新日期:2016-07-01 00:00:00
abstract::As pregnant women are at increased risk of influenza infection and influenza-related complications, immunization with inactivated influenza vaccine during the influenza season is recommended. Vaccination during pregnancy is considered to provide benefits for both the mothers and their young infants. In 2009, the novel...
journal_title:Expert review of vaccines
pub_type: 评论,杂志文章
doi:10.1586/erv.12.67
更新日期:2012-08-01 00:00:00
abstract::Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act as immune adjuvants, improving the immune response elicited by coadministered vaccines. Combining CpG ODN with anthrax vaccine adsorbed (AVA), the licensed human vaccine, can increase the speed, magnitude and avidity of the resultant anti-ant...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/14760584.5.3.365
更新日期:2006-06-01 00:00:00
abstract::Streptococcus pneumoniae (pneumococcus) is a major cause of worldwide mortality and morbidity, and to a large extent is vaccine-preventable. Nasopharyngeal carriage of pneumococcus precedes disease and is the source of pneumococcal spread between people. The use of vaccine effect on carriage as part of the vaccine lic...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/erv.12.53
更新日期:2012-07-01 00:00:00
abstract:BACKGROUND:Hepatitis A and B are two of the most common vaccine-preventable diseases and vaccination for Hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended for those at risk of contracting HAV and/or HBV through their occupation, travel or lifestyle. OBJECTIVE:To describe the vaccine efficacy, immunoge...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/14760584.2016.1150182
更新日期:2016-07-01 00:00:00
abstract::Dr Tamar Ben-Yedidia has more than 15 years of experience in the field of immunology, with specific expertise in the development of vaccines. She started her career with Biotechnology General Ltd (BTG; Rehovot, Israel), working on the development of a recombinant hepatitis B vaccine. She joined the Weizmann Institute ...
journal_title:Expert review of vaccines
pub_type: 面试
doi:10.1586/erv.10.2
更新日期:2010-03-01 00:00:00
abstract::Recombinant adenoviruses have emerged as promising viral vectors for CD8(+) T-cell vaccines. Our studies have indicated that unlike most acute infections, the CD8(+) T-cell memory population elicited by recombinant human adenovirus serotype 5 (rHuAd5) displays a dominant effector memory phenotype. Persistent, low-leve...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/erv.11.88
更新日期:2011-09-01 00:00:00
abstract::Immunocompromised hosts are growing in number and include transplant recipients of solid organs or hematopoietic stem cells, people who have HIV, cancer patients on chemotherapy, patients on immunomodulatory treatments for rheumatologic, gastrointestinal or other conditions, as well as those with other immunocompromis...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/14760584.7.5.663
更新日期:2008-07-01 00:00:00
abstract::Adjuvants are essential components of most clinically used vaccines. This is because the majority of nonliving vaccines are relatively poor inducers of adaptive immunity unless effective adjuvants are co-administered. Aluminum salts (alum) have been used as adjuvants with great success for almost a century and have be...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/erv.11.21
更新日期:2011-04-01 00:00:00
abstract::Baculovirus and insect cell culture technologies have mostly been limited to research laboratories for the transient expression of target proteins for drug development purposes. With the renaissance of the vaccine field and the regulatory acceptance of recombinant DNA technology, the baculovirus expression system has ...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/erv.11.24
更新日期:2011-07-01 00:00:00
abstract:INTRODUCTION:Pneumococcal conjugate vaccine (PCV) impact studies have reported substantial reductions in the incidence of invasive pneumococcal disease (IPD) after implementation of childhood PCV programs. Heterogeneity in surveillance systems, local epidemiology and PCV programs hampers comparisons between studies. We...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1080/14760584.2018.1413354
更新日期:2018-06-01 00:00:00
abstract::Pneumococcal disease is a major health problem worldwide. Large, rapid declines in overall invasive pneumococcal disease and mucosal disease in children, reductions in vaccine-type disease in unvaccinated children and adults (indirect effects) and significant drops in antibiotic-resistant infections were observed afte...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/14760584.7.9.1367
更新日期:2008-11-01 00:00:00
abstract:INTRODUCTION:Intranasal influenza vaccines are expected to confer protection among vaccine recipients by successful induction of mucosal immune response in the upper respiratory tract. Though only live attenuated influenza virus vaccines (LAIVs) are licensed and available for intranasal use in humans today, intranasal ...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1080/14760584.2018.1507743
更新日期:2018-08-01 00:00:00
abstract::Malaria continues to be a worldwide leading cause of morbidity and mortality, and the development of an effective malaria vaccine remains a research imperative. Of the multiple approaches that have been pursued, the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine for...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/erv.11.57
更新日期:2011-05-01 00:00:00
abstract::Introduction: Influenza vaccination is regarded as the most effective way to prevent influenza infection. Due to the rapid genetic changes that influenza viruses undergo, seasonal influenza vaccines must be reformulated and re-administered annually necessitating the evaluation of influenza vaccine effectiveness (VE) e...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1080/14760584.2019.1622419
更新日期:2019-06-01 00:00:00
abstract:INTRODUCTION:Streptococcus pneumoniae causes mucosal and invasive diseases with high morbidity and mortality. Introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) into routine infant immunization programs worldwide resulted in serotype 19A becoming a leading cause of the remaining pneumococcal disease bur...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1080/14760584.2017.1362339
更新日期:2017-10-01 00:00:00
abstract::In the Second Conference on Controversies in Vaccination in Adults, leading vaccine experts among manufacturers, physicians, microbiologists, virologists, immunologists and public health specialists came together to discuss recent approaches, developments and strategies in vaccination against worldwide pressing epidem...
journal_title:Expert review of vaccines
pub_type:
doi:10.1586/erv.13.44
更新日期:2013-06-01 00:00:00
abstract::There is growing interest in immunotherapy for malignant gliomas. This interest stems from a number of immunological observations, together with the failure of conventional therapeutic agents to produce broad and clinically meaningful improvements in survival and quality of life. The challenges faced in translating la...
journal_title:Expert review of vaccines
pub_type: 杂志文章,评审
doi:10.1586/14760584.2014.881255
更新日期:2014-03-01 00:00:00